SEC Form 4 · accession 0001225208-16-034453
WEST PHARMACEUTICAL SERVICES INC · WST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Malone
Officer — Vice President & Controller
Period of report
Jun 2, 2016
Accepted (ET)
Jun 2, 2016 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000105770
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 2, 2016 | M | 3,950 | $22.485 | A | 30,666 | D | |
| Common StockF1,F2 | Jun 2, 2016 | S | 3,950 | $74.9511 | D | 26,716 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $22.485 | Jun 2, 2016 | M | 3,950 | D | Feb 27, 2008 | Feb 27, 2017 | Common Stock | 3,950 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $74.76 to $75.08, inclusive. The reporting person undertakes to provide to West PharmaceuticalServices, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate pricewithin the range in this footnote.
- F2Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.